What does this procedure involve?

Anti-TNF induction therapy involves administering a biosimilar of adalimumab or infliximab via subcutaneous injection or intravenous infusion over a 12-week period. You will receive a total of 6 doses at scheduled intervals, typically in an outpatient clinic setting. The therapy targets tumor necrosis factor-alpha, a key driver of inflammation in conditions like Crohn's disease and ulcerative colitis. Our gastroenterology team monitors your response with regular blood tests and symptom assessments to ensure safety and efficacy.